
Grünenthal licenses exclusive Canadian rights to testosterone replacement therapy Nebido® to Apotex6.2.2026 08:21:37 EET | Grünenthal Group | Press release
Aachen, Germany & Toronto, Canada, February 5, 2026 – Grünenthal, a global leader in pain management and related diseases, and Apotex Inc. ("Apotex"), the largest Canadian-based pharmaceutical company, today announced they have entered into a licensing agreement whereby Apotex will have the exclusive Canadian rights to Nebido® (testosterone undecanoate), a long-acting injectable therapy indicated for the treatment of male hypogonadism (testosterone deficiency).[1] Under the agreement, Searchlight Pharma, Apotex's branded medicine division, will pursue marketing authorisation and will market and distribute the product in Canada upon regulatory approval. Grünenthal will receive an upfront payment, regulatory milestone payments, and a margin on the sales. This agreement deepens the existing partnership between Grünenthal and Apotex and strengthens their shared commitment to expanding Canadian patients' access to important therapies. "We are delighted to expand our partnership with Apotex
















